红霉素对解脲支原体肺炎的疗效及对细胞亚群和肝功能的影响

目的: 探讨红霉素对解脲支原体肺炎的疗效及对细胞亚群、肝功能的影响。方法: 收集我院2016年5月至2017年5月收治的41例解脲支原体肺炎患儿作为试验组，静脉滴注10 mg/kg红霉素与适量5%葡萄糖注射液，每天2次，疗程7～10 d，同期选取41例健康体检儿童，比较健康组与试验组治疗前后细胞亚群及肝功能，并分析试验组疗效及安全性。结果: 治疗前，试验组CD4+、CD4+/CD8+分别为（41.95±5.71）%、1.26±0.18，低于健康组的（48.13±7.21）%、1.79±0.20，试验组CD8+为（35.10±4.41）%，高于健康组的（26.56±3.13）%，试验组谷丙转氨酶、乳酸脱氢酶、总胆汁酸、胆红素、总胆固醇、甘油三酯、谷草转氨酶、谷丙转氨酶/谷草转氨酶分别为（136.71±17.20）U/L、（439.67±54.45）U/L、（28.39±3.72）U/L、（68.05±8.95）μmol/L、（7.82±0.95）mmol/L、（1.70±0.24）mmol/L、（113.37±14.25）U/L、1.24±0.14，高于健康组的（45.26±4.88）U/L、（397.98±47.20）U/L、（22.24±2.66）U/L、（36.71±4.83）μmol/L、（4.26±0.46）mmol/L、（1.24±0.17）mmol/L、（62.51±9.19）U/L、0.77±0.12；治疗后，试验组CD4+、CD4+/CD8+显著上升，CD8+、谷丙转氨酶、乳酸脱氢酶、总胆汁酸、胆红素、总胆固醇、甘油三酯、谷草转氨酶、谷丙转氨酶/谷草转氨酶显著下降，且两组比较无统计学差异（P>0.05）。结论: 红霉素对解脲支原体肺炎的疗效肯定，能够利于细胞亚群及肝功能的缓解。

Curative effect of erythromycin in the treatment of ureaplasma mycoplasma pneumonia and its influence on cell subset and liver function

AIM: To investigate the curative effect of erythromycin in the treatment of ureaplasma mycoplasma pneumonia and its influence on cell subset and liver function. METHODS: Forty-one cases of children patients with ureaplasma mycoplasma pneumonia that accepted from May 2016 to May 2017 were selected as experimental group. The children patients were given 10 mg/kg erythromycin and suitable amount of 5% glucose injection by intravenous infusion, twice per day, treatment for 7-10 days. Forty-one cases of healthy check-up newborns were selected as healthy group at the same time. Cell subsets and liver functions were compared between the healthy group and the experimental group before and after treatment, and the efficacy and safety in the experimental group were analyzed. RESULTS: Before treatment, the CD4+, CD4+/CD8+ of experimental group were (41.95±5.71)% and 1.26±0.18, which were lower than those in the healthy group of (48.13±7.21)% and 1.79±0.20.The CD8+ in experimental group was (35.10±4.41)%, which was higher than that in the healthy group (26.56±3.13)%, alanine aminotransferase, lactate dehydrogenase, total bile acid, bilirubin, total cholesterol, triglycerides, aspertate aminotransferase, Alt/aspertate aminotransferase in the experimental group were (136.71±17.20) U/L, (439.67±54.45) U/L, (28.39±3.72) U/L, (68.05±8.95) μmol/L, (7.82±0.95) mmol/L, (1.70±0.24) mmol/L, (113.37±14.25) U/L, 1.24±0.14, respectively,which were higher than those in the healthy group of (45.26±4.88) U/L, (397.98±47.20) U/L, (22.24±2.66) U/L, (36.71±4.83) μmol/L, (4.26±0.46) mmol/L, (1.24±0.17) mmol/L, (62.51±9.19) U/L, 0.77±0.12. After treatment, the levels of CD4+ and CD4+/CD8+ in the experimental group were significantly increased and the levels of CD8+, alanine aminotransferase, lactate dehydrogenase, total bile acid, bilirubin, total cholesterol, triglycerides, aspertate aminotransferase, alanine aminotransferase /aspertate aminotransferase in the treatment group were significantly decreased. However, there were no significant differences of those items between the two groups (P>0.05). CONCLUSION: Erythromycin has positive therapeutic effect on ureaplasma mycoplasma pneumonia, it helps cell subgroup and relieves liver function.